MENLO PARK, Calif.--(BUSINESS WIRE)--April 6, 2006--Geron Corporation (Nasdaq:GERN - News) announced presentations by collaborators and independent researchers at this year’s AACR Annual Meeting, including a preclinical study of its telomerase inhibitor drug, GRN163L, from the laboratory of Dr. Jerry Shay at the University of Texas Southwestern Medical Center, Dallas, Texas, and a clinical study of its telomerase vaccine, GRNVAC1, in advanced prostate cancer patients from the laboratory and clinic of Dr. Johannes Vieweg at Duke University Medical Center, Durham, North Carolina. In addition, there were more than 100 other presentations on telomerase and telomeres, reflecting the growing body of evidence supporting the importance of telomerase in cancer biology and its potential as a universal cancer target for drug and vaccine development.
